4//SEC Filing
KERYX BIOPHARMACEUTICALS INC 4
Accession 0001209191-05-022256
CIK 0001114220operating
Filed
Apr 25, 8:00 PM ET
Accepted
Apr 26, 5:21 PM ET
Size
7.3 KB
Accession
0001209191-05-022256
Insider Transaction Report
Form 4
KESSEL LARRY
Director
Transactions
- Other
Common Stock
2004-02-04$10.15/sh+4,926$49,999→ 10,926 total - Award
Stock Options (Right to Buy)
2003-06-23+25,000→ 25,000 totalExercise: $1.92From: 2013-06-23Exp: 2003-06-23→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]Mr. Kessel acquired shares of Keryx Biopharmaceuticals, Inc. common stock upon the conversion of the preferred shares he held in ACCESS Oncology, Inc. The conversion took place following Keryx Biopharmaceuticals, Inc.'s acquisition of ACCESS on February 4, 2004.
- [F2]5,000 of these options vested on June 23, 2003, and the remainder vested at a rate of 5,000 every quarter thereafter. All of Mr. Kessel's stock options reported on this Form 4 have vested and are exercisable.
Documents
Issuer
KERYX BIOPHARMACEUTICALS INC
CIK 0001114220
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001114220
Filing Metadata
- Form type
- 4
- Filed
- Apr 25, 8:00 PM ET
- Accepted
- Apr 26, 5:21 PM ET
- Size
- 7.3 KB